[1]陈功琦,梁道博.利培酮联合舍曲林治疗精神分裂症阴性症状 疗效和安全性的Meta分析[J].医学信息,2018,31(10):65-68,76.[doi:10.3969/j.issn.1006-1959.2018.10.020]
　CHEN Gong-qi,LIANG Dao-bo.Meta Analysis of Efficacy and Safety of Risperidone Combined with Sertraline in the Treatment of Schizophrenia with Negative Symptoms[J].Journal of Medical Information,2018,31(10):65-68,76.[doi:10.3969/j.issn.1006-1959.2018.10.020]
点击复制

利培酮联合舍曲林治疗精神分裂症阴性症状 疗效和安全性的Meta分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年10期
页码:
65-68,76
栏目:
论著
出版日期:
2018-05-15

文章信息/Info

Title:
Meta Analysis of Efficacy and Safety of Risperidone Combined with Sertraline in the Treatment of Schizophrenia with Negative Symptoms
文章编号:
1006-1959（2018）10-0065-05
作者:
陈功琦1; 梁道博2
1.山西医科大学第一临床医学院，山西 晋中 030600； 2.山西医科大学法医学院，山西 晋中 030600
Author(s):
CHEN Gong-qi1; LIANG Dao-bo2
1.The First Clinical Medical College,Shanxi Medical University,Jinzhong 030600,Shanxi,China; 2.Forensic Medical School,Shanxi Medical University,Jinzhong 030600,Shanxi,China
关键词:
精神分裂症; 阴性症状; 利培酮; 舍曲林; Meta分析
Keywords:
Key words：Schizophrenia; Negative symptoms; Risperidone; Sertraline; Meta analysis
分类号:
R749.3
DOI:
10.3969/j.issn.1006-1959.2018.10.020
文献标志码:
A
摘要:
目的 系统评价利培酮联合舍曲林治疗精神分裂症阴性症状的疗效和安全性。方法 计算机检索PubMed、EMbase、The Cochrane Library、CBM、WanFang Data和CNKI数据库，搜集有关利培酮联合舍曲林治疗精神分裂症阴性症状疗效和安全性的随机对照试验（RCT），检索时限从2007年1月~2017年9月。由两位评价员独立筛选文献、摄取资料并评价纳入研究的偏倚风险后，采用RevMan 5.3软件进行Meta分析。结果 最终纳入10个RCT，包括703个患者。Meta分析结果显示：与单用利培酮相比，利培酮联合舍曲林能明显提高有效率[RR=1.39，95%CI（1.26，1.54），P＜0.00001]，降低阳性与阴性统计量表（PANSS）总分[SMD=-0.46，95%CI（-0.69，-0.22），P=0.0001]及其阴性分[SMD=-0.73，95%CI（-0.98，-0.49），P＜0.00001]，降低阴性症状量表（SANS）评分[SMD=-0.67，95%CI（-0.91，-0.43），P＜0.00001]；对集中报道的不良反应（失眠、视物模糊，锥外体系反应、口干）发生率进行比较，差异无统计学意义（P＞0.05）。结论 利培酮联合舍曲林能提高对精神分裂症阴性症状的疗效，并不增加不良反应发生率。受纳入研究质量的限制，上述结论尚需开展更多高质量的研究予以验证。
Abstract:
Abstract：Objective To systematically evaluate the efficacy and safety of risperidone and sertraline in the treatment of negative symptoms of schizophrenia.Methods Computer searches PubMed,EMbase,The Cochrane Library,CBM,WanFang Data and CNKI databases to collect randomised controlled trials(RCT)on the efficacy and safety of risperidone and sertraline in the treatment of negative symptoms of schizophrenia.The search period is from January 2007 to September 2017.Two reviewers independently selected literature,ingested data,and assessed the risk of bias into the study,using RevMan 5.3 software for meta-analysis.Results The final inclusion of 10 RCT included 703 patients.Meta-analysis showed that risperidone combined with sertraline significantly increased the efficacy compared with risperidone alone[RR=1.39,95%CI(1.26,1.54),P<0.00001],and decreased positive and negative statistics. (PANSS)total score[SMD=-0.46,95% CI (-0.69,-0.22),P=0.0001]and its negative score[SMD=-0.73,95% CI(-0.98,-0.49),P<0.00001], Reduced Negative Symptom Scale(SANS)score[SMD=-0.67,95%CI(-0.91,-0.43),P<0.00001];There was no significant difference in the incidence of adverse reactions(insomnia,blurred vision,extra-conical system reaction,and dry mouth)reported in a concentrated manner (P>0.05).Conclusion Risperidone combined with sertraline can improve the efficacy of negative symptoms of schizophrenia without increasing the incidence of adverse reactions.Due to the limitations of the quality of the included studies,the above conclusions still need to be verified by more high-quality research.

参考文献/References:

[1]Owen MJ,Sawa A,Mortensen PB.Schizophrenia[J].Lancet,2016,388(10039):86-97.
[2]管丽丽,杜立哲,马弘.精神分裂症的疾病负担(综述)[J].中国心理卫生杂志,2012,26(12):913-919.
[3]王中刚.精神分裂症阴性症状治疗的研究进展[J].国际精神病学杂志,2011,38(01):48-51.
[4]Mitra S,Mahintamani T,Kavoor AR,et al.Negative symptoms in schizophrenia[J].Industrial Psychiatry Journal,2016,25(2):135-144.
[5]Moller HJ.The Relevance of Negative Symptoms in Schizophrenia and How to Treat Them with Psychopharmaceuticals[J].Psychiatria Danubina,2016,28(4):435-440.
[6]Higgins JP,Altman DG,Gotzsche PC,et al.The Cochrane Collaboration's tool for assessing risk of bias in randomised trials[J].BMJ,2011,343(7829):889-893.
[7]董健,张曦明.利培酮合并舍曲林治疗以阴性症状为主的精神分裂症的疗效观察[J].中国医师杂志,2010,12(10):1424-1425.
[8]江永.利培酮联合舍曲林治疗精神分裂症阴性症状临床研究[J].中国伤残医学,2013,21(7):60-61.
[9]解小永,杨向东.利培酮联合舍曲林治疗精神分裂症阴性症状对照研究[J].基层医学论坛,2013,11(17):2192-2194.
[10]孔庆伟.舍曲林联合利培酮治疗精神分裂症阴性症状的效果和安全性[J].中国社区医师,2016,32(5):19-20.
[11]李吉军.利培酮联合舍曲林治疗精神分裂症阴性症状的临床疗效[J].中国医药指南,2016,14(15):42.
[12]刘树国,张陆云,鲍晓玲.利培酮合并舍曲林治疗以阴性症状为主的精神分裂症的疗效观察[J].四川精神卫生,2007,20(02):118-119.
[13]宋长海.论利培酮联用舍曲林用于治疗阴性症状为主的精神分裂症的疗效分析[J].航空航天医学杂志,2014,25(05):601-602.
[14]谭来娣.舍曲林联合利培酮治疗精神分裂症阴性症状的临床观察[J].中外医疗,2014,33(17):129-130.
[15]魏冬,席永稳.利培酮联合舍曲林治疗以阴性症状为主的精神分裂症对照研究[J].临床心身疾病杂志,2016,3(22):44-46.
[16]姚明荣,袁天懿,查显友,等.舍曲林辅助治疗精神分裂症阴性症状40例[J].医药导报,2009,28(6):748-749.

相似文献/References:

[1]邹超杰,程宇琪.肠道微生物在精神分裂症中的研究进展[J].医学信息,2018,31(02):29.[doi:10.3969/j.issn.1006-1959.2018.02.011]
　ZOU Chao-jie,CHENG Yu-qi.Progress in the Study of Intestinal Microorganism in Schizophrenia[J].Journal of Medical Information,2018,31(10):29.[doi:10.3969/j.issn.1006-1959.2018.02.011]
[2]张 健,江 芮.生活技能训练对精神分裂症缓解期患者日常生活能力的影响[J].医学信息,2018,31(03):118.[doi:10.3969/j.issn.1006-1959.2018.03.040]
　ZHANG Jian,JIANG Rui.Effect of Life Skills Training on Daily Living Ability of Patients with Schizophrenia in Remission Staged[J].Journal of Medical Information,2018,31(10):118.[doi:10.3969/j.issn.1006-1959.2018.03.040]
[3]沈雪梅.齐拉西酮与奥氮平治疗首发精神分裂症 疗效及糖脂代谢的影响观察[J].医学信息,2018,31(06):130.[doi:10.3969/j.issn.1006-1959.2018.06.044]
　SHEN XUE-mei.The Effect of Ziprasidone and Olanzapine in the Treatment of First Episode Schizophrenia and the Effect of Glycolipid Metabolism[J].Journal of Medical Information,2018,31(10):130.[doi:10.3969/j.issn.1006-1959.2018.06.044]
[4]孙来顺.氨磺必利与利培酮对精神分裂症患者内分泌及糖脂代谢的影响[J].医学信息,2022,35(10):137.[doi:10.3969/j.issn.1006-1959.2022.10.033]
　SUN Lai-shun.Effects of Amisulpride and Risperidone on Endocrine And Glucose and Lipid Metabolism in Patients with Schizophrenia[J].Journal of Medical Information,2022,35(10):137.[doi:10.3969/j.issn.1006-1959.2022.10.033]
[5]孙占娟.精神分裂症患者的认知康复治疗进展[J].医学信息,2018,31(13):52.[doi:10.3969/j.issn.1006-1959.2018.13.015]
　SUN Zhan-juan.Progress in Cognitive Rehabilitation Therapy of Schizophrenia Patients[J].Journal of Medical Information,2018,31(10):52.[doi:10.3969/j.issn.1006-1959.2018.13.015]
[6]吴金丽.阿立哌唑的临床应用[J].医学信息,2018,31(14):42.[doi:10.3969/j.issn.1006-1959.2018.14.014]
　WU Jin-li.Clinical Application of Aripiprazole[J].Journal of Medical Information,2018,31(10):42.[doi:10.3969/j.issn.1006-1959.2018.14.014]
[7]宋典雄.激励理论指导下的护理干预对精神分裂症患者的影响[J].医学信息,2018,31(18):166.[doi:10.3969/j.issn.1006-1959.2018.18.054]
　SONG Dian-xiong.The Effect of Nursing Intervention under the Guidance of Motivation Theory on Patients with Schizophrenia[J].Journal of Medical Information,2018,31(10):166.[doi:10.3969/j.issn.1006-1959.2018.18.054]
[8]凌 梅,刘静芳.精神分裂症患者研究伙伴的相关研究进展[J].医学信息,2018,31(19):48.[doi:10.3969/j.issn.1006-1959.2018.19.016]
　LING Mei,LIU Jing-fang.Progress in Research on Research Partners in Patients with Schizophrenia[J].Journal of Medical Information,2018,31(10):48.[doi:10.3969/j.issn.1006-1959.2018.19.016]
[9]韩佳睿,张 苹,张 媛.迟发性运动障碍与DNA甲基化之间关系的研究进展[J].医学信息,2018,31(20):32.[doi:10.3969/j.issn.1006-1959.2018.20.010]
　HAN Jia-rui,ZHANG Ping,ZHANG Yuan.Advances in Research on the Relationship between Tardive Dyskinesia and DNA Methylation[J].Journal of Medical Information,2018,31(10):32.[doi:10.3969/j.issn.1006-1959.2018.20.010]
[10]陈宽玉,孔 骞,黄玉桃.首发缓解期精神分裂症患者日常生活模式的调查[J].医学信息,2019,32(04):182.[doi:10.3969/j.issn.1006-1959.2019.04.061]
　CHEN Kuan-yu,KONG Qian,HUANG Yu-tao.Investigation on the Daily Life Pattern of Patients with Schizophrenia in the First Remission Period[J].Journal of Medical Information,2019,32(10):182.[doi:10.3969/j.issn.1006-1959.2019.04.061]
[11]孙来顺.氨磺必利治疗阴性症状为主的精神分裂症患者的疗效[J].医学信息,2021,34(22):136.[doi:10.3969/j.issn.1006-1959.2021.22.042]
　SUN Lai-shun.Efficacy of Amisulpride in the Treatment of Schizophrenia Patients with Negative Symptoms[J].Journal of Medical Information,2021,34(10):136.[doi:10.3969/j.issn.1006-1959.2021.22.042]
[12]孙来顺.氨磺必利与利培酮治疗精神分裂症阴性症状的疗效比较[J].医学信息,2022,35(07):121.[doi:10.3969/j.issn.1006-1959.2022.07.030]
　SUN Lai-shun.Comparison of Therapeutic Effects of Amisulpride and Risperidone on Negative Symptoms of Schizophrenia[J].Journal of Medical Information,2022,35(10):121.[doi:10.3969/j.issn.1006-1959.2022.07.030]
[13]王 震.氯氮平与氯丙嗪治疗维持期精神分裂症患者的临床疗效及安全性比较[J].医学信息,2023,36(03):152.[doi:10.3969/j.issn.1006-1959.2023.03.032]
　WANG Zhen.Comparison of Clinical Efficacy and Safety of Clozapine and Chlorpromazine in the Treatment of Patients with Maintenance Schizophrenia[J].Journal of Medical Information,2023,36(10):152.[doi:10.3969/j.issn.1006-1959.2023.03.032]

更新日期/Last Update: 2018-05-15